PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2018.1912019512611-622Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin LymphomasSeok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kimhttp://e-crt.org/upload/pdf/crt-2018-191.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2018.191, http://www.e-crt.org/upload/pdf/crt-2018-191.pdf
Haematologica10.3324/haematol.2021.2783012021A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomasMiso Kim, Jeong-Ok Lee, Jiwon Koh, Tae Min Kim, Ji Yun Lee, Yoon Kyung Jeon, Bhumsuk Keam, Dong-Wan Kim, Jong Seok Lee, Dae Seog Heohttps://haematologica.org/article/download/haematol.2021.278301/73231, https://haematologica.org/article/download/haematol.2021.278301/73231
Reactions Weekly10.1007/s40278-020-85104-420201828128-28Alemtuzumab/fludarabinehttp://link.springer.com/content/pdf/10.1007/s40278-020-85104-4.pdf, http://link.springer.com/article/10.1007/s40278-020-85104-4/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-020-85104-4.pdf
Histopathology10.1046/j.1365-2559.2000.00843.x2000363252-261Epstein-Barr virus and gastric carcinoma in Western patients: comparison of pathological parameters and p53 expression in EBV-positive and negative tumours Chapel, Fabiani, Davi, Raphael, Tepper, Champault, Guettierhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2559.2000.00843.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2559.2000.00843.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2559.2000.00843.x/fullpdf
Comparative Clinical Pathology10.1007/s00580-007-0710-22008172125-131Prognostic significance of cyclooxygenase-2 expression in pediatric Hodgkin and non-Hodgkin lymphomas with or without Epstein–Barr virus latent infectionSafiye Aktaş, Aydanur Kargı, Nur Olgun, Gulden Diniz, Ayşe Erbay, Canan Verginhttp://link.springer.com/content/pdf/10.1007/s00580-007-0710-2.pdf, http://link.springer.com/article/10.1007/s00580-007-0710-2/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00580-007-0710-2
Histopathology10.1111/j.1365-2559.2011.03905.x2011592352-355Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphomaYu-Yan Hwang, Anskar Y H Leung, Wing-Hung Lau, Florence Loong, Jason C C So, Eric Tse, Yok-Lam Kwonghttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2559.2011.03905.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2559.2011.03905.x/fullpdf
OncoTargets and Therapy10.2147/ott.s340552014865Pixantrone for the treatment of adult patients with relapsed or refractory aggressive non-Hodgkin B-cell lymphomasStefano Volpetti, Renato Fanin, Francesco Zajahttps://www.dovepress.com/getfile.php?fileID=20281
The Lancet Oncology10.1016/s1470-2045(21)00251-52021226e234Pembrolizumab for relapsed or refractory Hodgkin lymphomaAlessandro Pulsonihttps://api.elsevier.com/content/article/PII:S1470204521002515?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1470204521002515?httpAccept=text/plain
Reactions Weekly10.1007/s40278-019-68797-820191773140-40Antineoplastics/immunosuppressantshttp://link.springer.com/content/pdf/10.1007/s40278-019-68797-8.pdf, http://link.springer.com/article/10.1007/s40278-019-68797-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s40278-019-68797-8.pdf
Medical Microbiology and Immunology10.1007/bf0019389919871763Antibodies to the second Epstein-Barr virus nuclear antigen in non-Hodgkin lymphomasL. Gergely, J. Czegl�dy, L. V�czi, K. P�l�czi, G. Szegedihttp://link.springer.com/content/pdf/10.1007/BF00193899.pdf, http://link.springer.com/article/10.1007/BF00193899/fulltext.html, http://link.springer.com/content/pdf/10.1007/BF00193899